Test-retest repeatability of organ uptake on PSMA-targeted 18 F-DCFPyL PET/CT in patients with prostate cancer.
Prostate
; 83(12): 1186-1192, 2023 09.
Article
in En
| MEDLINE
| ID: mdl-37211963
ABSTRACT
OBJECTIVES:
We evaluated 18 F-DCFPyL test-retest repeatability of uptake in normal organs.METHODS:
Twenty-two prostate cancer (PC) patients underwent two 18 F-DCFPyL PET scans within 7 days within a prospective clinical trial (NCT03793543). In both PET scans, uptake in normal organs (kidneys, spleen, liver, and salivary and lacrimal glands) was quantified. Repeatability was determined by using within-subject coefficient of variation (wCOV), with lower values indicating improved repeatability.RESULTS:
For SUVmean , repeatability was high for kidneys, spleen, liver, and parotid glands (wCOV, range 9.0%-14.3%) and lower for lacrimal (23.9%) and submandibular glands (12.4%). For SUVmax , however, the lacrimal (14.4%) and submandibular glands (6.9%) achieved higher repeatability, while for large organs (kidneys, liver, spleen, and parotid glands), repeatability was low (range 14.1%-45.2%).CONCLUSION:
We found acceptable repeatability of uptake on 18 F-DCFPyL PET for normal organs, in particular for SUVmean in the liver or parotid glands. This may have implications for both PSMA-targeted imaging and treatment, as patient selection for radioligand therapy and standardized frameworks for scan interpretation (PROMISE, E-PSMA) rely on uptake in those reference organs.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Positron Emission Tomography Computed Tomography
Type of study:
Observational_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Prostate
Year:
2023
Type:
Article
Affiliation country:
Germany